Advertisement
UK markets close in 7 minutes

  • FTSE 100

    8,346.35
    -23.98 (-0.29%)
     

  • FTSE 250

    20,673.68
    -36.39 (-0.18%)
     

  • AIM

    804.22
    +0.35 (+0.04%)
     

  • GBP/EUR

    1.1742
    -0.0006 (-0.05%)
     

  • GBP/USD

    1.2712
    -0.0008 (-0.06%)
     

  • Bitcoin GBP

    53,591.43
    -1,544.26 (-2.80%)
     

  • CMC Crypto 200

    1,467.23
    -35.44 (-2.36%)
     

  • S&P 500

    5,313.44
    +6.43 (+0.12%)
     

  • DOW

    39,362.50
    -308.54 (-0.78%)
     

  • CRUDE OIL

    77.33
    -0.24 (-0.31%)
     

  • GOLD FUTURES

    2,344.90
    -48.00 (-2.01%)
     

  • NIKKEI 225

    39,103.22
    +486.12 (+1.26%)
     

  • HANG SENG

    18,868.71
    -326.89 (-1.70%)
     

  • DAX

    18,682.46
    +2.26 (+0.01%)
     

  • CAC 40

    8,096.42
    +4.31 (+0.05%)
     
Money:

What does the UK general election mean for your finances?

Implications of a snap election on your pensions, savings, tax and investments

Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?

Zacks Equity Research
·2-min read

Investors are always looking for stocks that are poised to beat at earnings season and Black Diamond Therapeutics, Inc. BDTX may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Black Diamond Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for BDTX in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 41 cents per share for BDTX, narrower than the broader Zacks Consensus Estimate of a loss of 44 cents per share. This suggests that analysts have very recently bumped up their estimates for BDTX, giving the stock a Zacks Earnings ESP of +5.75% heading into earnings season.

Black Diamond Therapeutics, Inc. Price and EPS Surprise

Black Diamond Therapeutics, Inc. Price and EPS Surprise
Black Diamond Therapeutics, Inc. Price and EPS Surprise

Black Diamond Therapeutics, Inc. price-eps-surprise | Black Diamond Therapeutics, Inc. Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that BDTX has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Black Diamond Therapeutics, and that a beat might be in the cards for the upcoming report.

ADVERTISEMENT

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Black Diamond Therapeutics, Inc. (BDTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research